HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, has released both an operational update and the filing of its annual and fourth-quarter financial results for the fiscal year ended December 31, 2020. Company highlights include being ranked no. 2 in Brightfield Group’s most recent survey in the CBD Brand Awareness (U.S.) category, as well as SPINS naming its proprietary Probulin Probiotics product fastest-growing probiotic brand in 2020 out of the top 10 in the country. Other highlights included being the no. 2 CBD holding in AdvisorShares Pure US Cannabis ETF, being one of only a few companies to offer OTC drug-listed topical products, and having its OTC Tropical products ranked top in both sales dollars and units sold at a major U.S. food & drug mass retailer. In addition, HempFusion completed a digital relaunch, which increased online traffic by 10 times; completed a $17,000,000 initial public offering (“IPO”); commenced trading on the Toronto Stock Exchange, becoming the first U.S.-based CBD & wellness products company to list directly on the TSX; and launched the Probulin store on Amazon. “COVID and continued lack of clarity from the FDA related to official regulatory guidance for CBD used in dietary supplements, foods, and beverages has made 2020 a challenging year,” the company reported in the press release. “However, these challenges have led to strategic changes, establishing the foundation for HempFusion to succeed in 2021 and beyond. There are no quick and easy ways to navigate this dynamic and emerging industry. The company remains focused and highly optimistic that the five-channel strategy and international expansion will drive significant success throughout 2021 and beyond.”
To view the full press releases, visit https://ibn.fm/cbqGj and https://ibn.fm/pk7t1
About HempFusion Wellness Inc.
HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research and HF Labs, to approximately 4,000 retailers across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 46 SKUs (“SKUs”) including tinctures, proprietary FDA Drug Listed over-the-counter (“OTC”) topicals, doctor/practitioner lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion’s wholly owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex(TM) and are available in stores or online. For more information about the company, visit www.HempFusion.com.
NOTE TO INVESTORS: The latest news and updates relating to CBDHF are available in the company’s newsroom at https://ibn.fm/CBDHF
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
